The Conversation (0)
August 28, 2025
INN Article Notification
29 July 2025
Quarterly Activities/Appendix 4C Cash Flow Report
Radiopharm Theranostics (RAD:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
27 July 2025
RAD receives IND approval from US FDA for Betabart (RV-01)
Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)Download the PDF here. Keep Reading...
10 June 2025
RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases ImagingDownload the PDF here. Keep Reading...
03 June 2025
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202Download the PDF here. Keep Reading...
01 June 2025
RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
Radiopharm Theranostics (RAD:AU) has announced RAD Reports Positive Preclinical Lu177-B7H3-mAb DataDownload the PDF here. Keep Reading...
22h
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today... Keep Reading...
29 April
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's... Keep Reading...
28 April
Fit to Work: GLP-1 and Metabolic Health in the M&A Sector
Biotechnology, pharmaceutical and medtech companies each contributed about 30 percent of deal volume to overall mergers and acquisitions (M&A) activity in 2025.The surge is attributed to rising obesity and diabetes cases, with the 2025 World Obesity Atlas projecting that the total number of... Keep Reading...
23 April
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Contracts signed for Animal Study #2: GLP-1-A26-2Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is... Keep Reading...
22 April
Top 3 Canadian Biotech Stocks in 2026
Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here the Investing News Network profiles the three best-performing Canadian biotech stocks... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00